A Study for Clinical Efficacy of GnRH Antagonist (Cetrorelix) Combined Minimal Stimulation Protocol and GnRH Agonist Combined Long Protocol in Assisted Reproductive Techniques for ICSI Cycles.

Objective : The aim of this study was to evaluate the outcomes of the GnRH antagonist (Cetrorelix) minimal stimulation protocol comparing with GnRH agonist combined with long stimulation protocol in male infertility patients. Methods : From Jan 2002 to Jun 2003, 65 patients (65 cycles) were performed in controlled ovarian hyperstimulation by using GnRH antagonist and GnRH agonist for male infertility patients. GnRH antagonist combined with minimal stimulation protocol was administered in 30 patients (30 cycles, Study Group) and GnRH agonist long stimulation protocol was administered in 35 patients (35 cycles, Control Group). We compared the pregnancy rate/cycle, total hMG(A)/cycle, retrieved oocyte/cycle, and the incidence of ovarian hyperstimulation syndrome between the two groups. Student-t test was used to determine statistical significance. Statistical significance was defined as p0.6 in the GnRH antagonist group and 8.41.8 in the GnRH agonist group. Fertilization rates were 82.517.7% and 79.420.2% in the GnRH antagonist and agonist group, respectively. The GnRH antagonist group used a lower dose of hMG (8.51.2 vs 39.410.7 ample/cycle) and none of them developed OHSS. Clinical pregnancy rates per cycle were 23.3% in GnRH antagonist group and 31.4% GnRH agonist group. Conclusion : GnRH antagonist protocol may be presented as a new controlled ovarian hyperstimulation protocol which has been applied to male-factor infertility undergoing ICSI.